Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Parathyroid hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    120 result(s) found for: Parathyroid hormone. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2015-000411-40 Sponsor Protocol Number: Version1.0 Start Date*: 2015-10-23
    Sponsor Name:Department of Nuclear Medicine and Endocrinology, Paracelsus Medical University Salzburg
    Full Title: Comparison of the detection of parathyroid adenoms using Tc-99m MIBI scintigraphy and F-18 Choline PET/CT in patients with primary hyperparathyroidism
    Medical condition: Primary hyperparathyroidism due to parathyroid adenoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003067-36 Sponsor Protocol Number: SHP634-404 Start Date*: 2018-06-28
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects with Hypoparathyroidism.
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051315 Congenital hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10075900 Primary hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10021041 Hypoparathyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001265-40 Sponsor Protocol Number: PAR-C10-009 Start Date*: 2011-07-29
    Sponsor Name:NPS Pharmaceuticals, Inc.
    Full Title: A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults with Hypoparathyroidism - A Clin...
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    13.1 10014698 - Endocrine disorders 10021041 Hypoparathyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-000284-32 Sponsor Protocol Number: SHP634-401 Start Date*: 2018-02-05
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinan...
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051315 Congenital hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10075900 Primary hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10021041 Hypoparathyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) SE (Completed) DK (Completed) ES (Completed) NO (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003108-22 Sponsor Protocol Number: PAR-C14-007 Start Date*: 2015-12-08
    Sponsor Name:NPS Pharmaceuticals, Inc.
    Full Title: An Open-label, Single-dose Study to Determine the Pharmacokinetic/Pharmacodynamic Profile of Parathyroid Hormone (rDNA) Administered Subcutaneously at a Dose of 50 µg in Subjects with Hypoparathyr...
    Medical condition: Chronic hypoparathyroidism
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002729-31 Sponsor Protocol Number: PETCOLINA1-FINBA Start Date*: 2020-03-02
    Sponsor Name:Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturias (FINBA)
    Full Title: 18F-fluorocholine PET/CT in primary hyperparathyroidism with negative preoperative localization
    Medical condition: Primary hyperthyroidism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10036693 Primary hyperparathyroidism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005063-34 Sponsor Protocol Number: CL1-11-040 Start Date*: 2009-09-14
    Sponsor Name:NPS Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP 558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)] for the Treatment of Adults with Hypoparathyr...
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021041 Hypoparathyroidism LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) BE (Completed) GB (Completed) IT (Completed) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-020081-22 Sponsor Protocol Number: R&D 2185 Start Date*: 2011-02-08
    Sponsor Name:North Bristol NHS Trust
    Full Title: The administration of Parathyroid hormone affects functional recovery from pertrochanteric fractured neck of femur: A prospective randomised comparative pilot study with blinded objective functiona...
    Medical condition: Osteoporotic or low energy pertrochanteric hip fractures
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001890-26 Sponsor Protocol Number: TRACTOR Start Date*: 2014-05-06
    Sponsor Name:Dipartimento di Medicina e Chirurgia Traslazionale dell’Università degli Studi di Firenze
    Full Title: Recombinant human parathyroid hormone [rh PTH(1-34): Teriparatide] as therapy for refractory hypoparathyroidism
    Medical condition: Refractory hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10021041 Hypoparathyroidism PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004465-32 Sponsor Protocol Number: 2011/386 Start Date*: 2011-12-12
    Sponsor Name:Dept. of Cardiothoracic & Vascular Surgery, Aarhus University Hospital, Skejby
    Full Title: Can post-operative treatment with parathyroid hormone enhance bone healing and quality of newly formed bone after sternotomy in cardiac surgery patients?
    Medical condition: Sternotomy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10051332 Surgical procedure LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000606-36 Sponsor Protocol Number: 84421383 Start Date*: 2008-04-07
    Sponsor Name:Aarhus University Hospital, Dept of Endocrinology and Metabolism C
    Full Title: Treatment of hypoparathyroidism with subcutaneous PTH (1-84) injections: effects on muscle function and quality of life
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021041 Hypoparathyroidism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004316-73 Sponsor Protocol Number: 3189 Start Date*: 2006-08-23
    Sponsor Name:Royal Liverpool University hospital
    Full Title: The effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A ...
    Medical condition: Osteoporosis and Reduced Bone mineral density (T scores< -1.0 on DEXA scan), Adult growth hormone deficiency ( GH levels,9mU/l on Insulin stress test) with reduced BMD (T scores< -1.0 on DEXA scan)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005683-21 Sponsor Protocol Number: ENM-EA-030 Start Date*: 2012-10-09
    Sponsor Name:Medizinische Universität Graz
    Full Title: Effects of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
    Medical condition: Primary hyperparathyroidism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000640-10 Sponsor Protocol Number: GPR-II-18-1 Start Date*: 2019-10-10
    Sponsor Name:LABORATOIRES SMB S.A.
    Full Title: A phase II, randomised, double-blind, and parallel study to estimate the dose-response of vitamin D supplementation in chronic kidney disease patients with secondary hyperparathyroidism and vitamin...
    Medical condition: chronic kidney disease, stage 3 with secondary hyperparathyroidism and vitamin D deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10038430 Renal disorders (excl nephropathies) HLGT
    20.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-011883-12 Sponsor Protocol Number: I2Y-MC-GHFA(c) Start Date*: 2009-08-26
    Sponsor Name:Elli Lilly and Company
    Full Title: A Phase 2 Study for Transdermal Application of Teriparatide
    Medical condition: Treatment of osteoporosis in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005374-57 Sponsor Protocol Number: Calcimimetics Start Date*: 2013-02-15
    Sponsor Name:Department of Breast and Endocrine Surgery, Karolinska University Hospital
    Full Title: Primary hyperparathyroidism: Short-term calcimimetics treatment – Relevance for parathyroid surgery decisions?
    Medical condition: Primary hyperparathyroidism (PHPT) is a common disease, characterized by a high-normal calcium concentration and an inappropriately increased parathyroid hormone (PTH) level
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004860 10036693 Primary hyperparathyroidism LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004136-30 Sponsor Protocol Number: 20130213 Start Date*: 2014-03-05
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    18.0 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) BE (Completed) AT (Completed) ES (Completed) PT (Completed) LT (Completed) PL (Completed) CZ (Completed) DK (Completed) LV (Completed) DE (Completed) GR (Completed) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002610-13 Sponsor Protocol Number: M11-612 Start Date*: 2013-12-06
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 with Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hem...
    Medical condition: - Stage 5 chronic kidney disease - Secondary to hyperparathyroidism
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000178-24 Sponsor Protocol Number: W2021.040 Start Date*: 2023-10-20
    Sponsor Name:
    Full Title: Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial.
    Medical condition: patients with secondary hyperparathyroidism after Roux-en-Y gastric bypass surgery (RYGB).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002808-41 Sponsor Protocol Number: 20120231(KAI-4169-008) Start Date*: 2013-01-22
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemod...
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    16.1 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) GB (Completed) SE (Completed) ES (Completed) IT (Completed) AT (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 11:42:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA